GSK slams NICE's rejection of Benlysta in SLE in final draft guidance
This article was originally published in Scrip
Executive Summary
The health technology appraisal body in England and Wales, NICE, has turned down GlaxoSmithKline/ Human Genome Science's systemic lupus erythematosus (SLE) treatment, Benlysta (belimumab), within its licensed indication, in its final draft guidance.